Lok Lam Ngai

1.4k total citations
17 papers, 370 citations indexed

About

Lok Lam Ngai is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Hematology. According to data from OpenAlex, Lok Lam Ngai has authored 17 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 8 papers in Surgery and 8 papers in Hematology. Recurrent topics in Lok Lam Ngai's work include Gastric Cancer Management and Outcomes (9 papers), Acute Myeloid Leukemia Research (8 papers) and Esophageal Cancer Research and Treatment (7 papers). Lok Lam Ngai is often cited by papers focused on Gastric Cancer Management and Outcomes (9 papers), Acute Myeloid Leukemia Research (8 papers) and Esophageal Cancer Research and Treatment (7 papers). Lok Lam Ngai collaborates with scholars based in Netherlands, United States and Italy. Lok Lam Ngai's co-authors include Hanneke W.M. van Laarhoven, Martijn G.H. van Oijen, Nadia Haj Mohammad, Emil ter Veer, Gert van Valkenhoef, Gert J. Ossenkoppele, Maarten Anderegg, Jacqueline Cloos, Jeroen J. W. M. Janssen and Angèle Kelder and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Lok Lam Ngai

17 papers receiving 366 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lok Lam Ngai Netherlands 9 178 130 116 98 54 17 370
Geundoo Jang South Korea 12 159 0.9× 92 0.7× 208 1.8× 68 0.7× 32 0.6× 39 396
Chen‐Yuan Lin Taiwan 9 84 0.5× 148 1.1× 121 1.0× 38 0.4× 84 1.6× 24 333
Senaka Peter United States 7 72 0.4× 87 0.7× 87 0.8× 104 1.1× 40 0.7× 17 308
Eric Beohou France 12 69 0.4× 61 0.5× 144 1.2× 247 2.5× 68 1.3× 18 385
Shanbo Cao China 9 77 0.4× 46 0.4× 68 0.6× 40 0.4× 74 1.4× 46 219
Toshinori Okuda Japan 8 102 0.6× 98 0.8× 98 0.8× 48 0.5× 12 0.2× 30 218
Y Hiki Japan 14 243 1.4× 154 1.2× 48 0.4× 37 0.4× 86 1.6× 37 469
M. Karina Greece 8 119 0.7× 63 0.5× 180 1.6× 25 0.3× 21 0.4× 12 277
E. van Meerten Netherlands 11 238 1.3× 276 2.1× 280 2.4× 21 0.2× 67 1.2× 15 499
A. Millà Spain 10 132 0.7× 151 1.2× 183 1.6× 16 0.2× 56 1.0× 15 367

Countries citing papers authored by Lok Lam Ngai

Since Specialization
Citations

This map shows the geographic impact of Lok Lam Ngai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lok Lam Ngai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lok Lam Ngai more than expected).

Fields of papers citing papers by Lok Lam Ngai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lok Lam Ngai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lok Lam Ngai. The network helps show where Lok Lam Ngai may publish in the future.

Co-authorship network of co-authors of Lok Lam Ngai

This figure shows the co-authorship network connecting the top 25 collaborators of Lok Lam Ngai. A scholar is included among the top collaborators of Lok Lam Ngai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lok Lam Ngai. Lok Lam Ngai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Ngai, Lok Lam, Willemijn J. Scholten, Angèle Kelder, et al.. (2024). The role of the primitive marker CD133 in CD34‐negative acute myeloid leukemia for the detection of leukemia stem cells. Cytometry Part B Clinical Cytometry. 108(1). 23–34. 3 indexed citations
2.
Tettero, Jesse M., Angèle Kelder, Willemijn J. Scholten, et al.. (2024). Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia. Leukemia. 38(3). 630–639. 8 indexed citations
3.
Kelder, Angèle, Lok Lam Ngai, Patrycja Gradowska, et al.. (2024). Computational assessment of measurable residual disease in acute myeloid leukemia using mixture models. SHILAP Revista de lepidopterología. 4(1). 271–271. 3 indexed citations
4.
Rodríguez‐Arbolí, Eduardo, Megan Othus, Sylvie Freeman, et al.. (2024). Optimal Prognostic Threshold for Acute Myeloid Leukemia (AML) Measurable Residual Disease (MRD) Positivity By Multiparameter Flow Cytometry: A Report of 2,051 Patients from MRC/NCRI, Gimema, HOVON, and Seattle. Transplantation and Cellular Therapy. 30(2). S9–S9. 2 indexed citations
5.
Cloos, Jacqueline, Lok Lam Ngai, & Michael Heuser. (2023). Understanding differential technologies for detection of MRD and how to incorporate into clinical practice. Hematology. 2023(1). 682–690. 5 indexed citations
6.
Tettero, Jesse M., Lok Lam Ngai, Costa Bachas, et al.. (2022). Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching. Blood. 140(Supplement 1). 2027–2029. 1 indexed citations
7.
Ngai, Lok Lam, Angèle Kelder, Jeroen J. W. M. Janssen, Gert J. Ossenkoppele, & Jacqueline Cloos. (2021). MRD Tailored Therapy in AML: What We Have Learned So Far. Frontiers in Oncology. 10. 603636–603636. 42 indexed citations
8.
Walter, Roland B., Yishai Ofran, Agnieszka Wierzbowska, et al.. (2021). Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. Leukemia. 35(6). 1529–1538. 52 indexed citations
9.
Kleef, Jessy Joy van, Emil ter Veer, Héctor G. van den Boorn, et al.. (2019). Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis. JNCI Journal of the National Cancer Institute. 112(1). 12–29. 40 indexed citations
10.
Ngai, Lok Lam, Emil ter Veer, Héctor G. van den Boorn, et al.. (2019). TOXview: a novel graphical presentation of cancer treatment toxicity profiles. Acta Oncologica. 58(8). 1138–1148. 5 indexed citations
11.
Veer, Emil ter, Lok Lam Ngai, Gert van Valkenhoef, et al.. (2017). Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis. Scientific Reports. 7(1). 7142–7142. 20 indexed citations
12.
Veer, Emil ter, Nadia Haj Mohammad, Paul Lodder, et al.. (2016). The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 19(3). 696–712. 30 indexed citations
13.
Veer, Emil ter, Nadia Haj Mohammad, Gert van Valkenhoef, et al.. (2016). Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature. Cancer and Metastasis Reviews. 35(3). 439–456. 32 indexed citations
14.
Veer, Emil ter, Nadia Haj Mohammad, Gert van Valkenhoef, et al.. (2016). The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis. JNCI Journal of the National Cancer Institute. 108(10). djw166–djw166. 86 indexed citations
15.
16.
Mohammad, Nadia Haj, et al.. (2015). First-line doublet or triplet chemotherapy for advanced esophagogastric cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology. 33(15_suppl). e15090–e15090. 1 indexed citations
17.
Veer, Emil ter, Nadia Haj Mohammad, Gert van Valkenhoef, et al.. (2015). 2369 Efficacy and safety of first line chemotherapy in Advanced EsophagoGastric Cancer (AEGC): A network meta-analysis. European Journal of Cancer. 51. S459–S459. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Geundoo Jang Breakdown of academic impact, for papers by Chen‐Yuan Lin Breakdown of academic impact, for papers by Senaka Peter Breakdown of academic impact, for papers by Eric Beohou Breakdown of academic impact, for papers by Shanbo Cao Breakdown of academic impact, for papers by Toshinori Okuda Breakdown of academic impact, for papers by Y Hiki Breakdown of academic impact, for papers by M. Karina Breakdown of academic impact, for papers by E. van Meerten Breakdown of academic impact, for papers by A. Millà
Rankless by CCL
2026